This satellite symposium was organised and sponsored by BMS and is intended for healthcare professionals only. Speakers were compensated for their participation at this event.
Prescribing information and adverse events reporting is available at the bottom of this page.
โS1P Receptor Modulators in Ulcerative Colitis: A Growing Track Record in the Moderate UC Patientโ, a BMS promotional symposium that took place at the United European Gastroenterology (UEG) Week 2024, focuses on the pressing challenges and unmet needs in treating moderate ulcerative colitis (UC), and aims to educate healthcare providers on the evolving role of sphinogosine-1-phosphate (S1P) receptor modulators in UC management. The session explores recent clinical trial findings and real-world data to provide novel insights on the efficacy of these drugs.
Ailsa Hart opens with an overview of UC and the current treatment landscape, with a special focus on the moderate UC patient profile and the need for innovative approaches.
Michael Chiorean discusses the role of S1P receptor modulators in moderate UC management, highlighting key findings from relevant studies. This includes True North, a 52-week, randomised, double-blind, placebo-controlled Phase III trial assessing ozanimodโผ in moderate-to-severe UC across 30 countries, and Japan True-North, a Phase II/III study exploring ozanimodโs efficacy and safety in Japanese patients with active UC.1-4
Irina Blumenstein presents data from the ELEVATE clinical trials, which assessed the safety and efficacy of daily etrasimod, a once-daily oral S1P receptor modulator, in adults with moderate-to-severe UC. ELEVATE was conducted as a two-part independent, randomised, multicentre, double-blind, placebo-controlled Phase III trials (ELEVATE UC 52 and ELEVATE UC 12).5
An interesting question and answer period wraps up the symposium.
Timestamps:
- 00:00-01:24 – Welcome and Introductions
- 01:25-08:01 – UC Overview and Treatment Paradigm – Special Focus on the Moderate Patient
- 08:02-13:49 – Current Role of S1P Receptor Modulators in Moderate UC
- 13:50-30:18 – S1P Receptor Modulator Clinical Trials: True North and Japan-True North
- 30:19-49:27 – S1P Receptor Modulator Clinical Trials: ELEVATE
- 49:28-1:00:24 – Interactive Session and Q&A
Speakers
Ailsa Hart1
Irina Blumenstein2
Michael Chiorean3
1. Director and Consultant Gastroenterologist, St. Markโs Hospital Inflammatory Bowel Disease Research, and Past Dean, St Markโs Hospital Academic Institute, London, UK; Professor of Practice, Imperial College London, UK; and Honorary Skou Professor, University of Aarhus, Denmark
2. Head, IBD University Outpatient Clinic and Clinical Study Department and Consultant Gastroenterologist, Goethe University, Frankfurt, Germany; and University Hospital Medical Clinic 1, Frankfurt, Germany
3. Director, IBD Center Digestive Health Institute, Swedish Medical Center, Seattle, Washington, USA
Click here for Zeposiaยฎ
โผ(ozanimod) Prescribing Information (UK)
Click here for Zeposiaยฎโผ(ozanimod) Prescribing Information (Ireland)
โผThis medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
For Healthcare Professionals only. This symposium was organised and funded by Bristol Myers Squibb. BMS medicines and/or product information may be discussed. IMM-GB-2400112 | Date of Prep: April 2024
| Adverse events should be reported. Reporting forms and information can be found via: Great Britain & Northern Ireland โ The Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App store; Ireland โ HPRA Pharmacovigilance at www.hpra.ie Adverse events should also be reported to Bristol-Myers Squibb via [email protected] or 08007311736 (Great Britain & Northern Ireland); 1 800 749 749 (Ireland). |
References:
1. Sandborn WJ et al.; True North Study Group. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021;385(14):1280-91.
2.ย ZEPOSIA U.S. Prescribing Information. 2024. Available at: https://packageinserts.bms.com/pi/pi_zeposia.pdf. Last accessed: 5 November 2024.
3. Zeposia (ozanimod). EMC Summary of product characteristics. 2024. Available at: https://www.medicines.org.uk/emc/product/11908/smpc#gref. Last accessed 10 December 2024.
4. Nakase et al. Ozanimod as induction and maintenance therapy for ulcerative colitis: a randomized, double-blind, placebo-controlled study in Japan (J-True North). Abstract Su1795. DDW, May 18-21, 2024.
5. Sandborn WJ et al. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023;401(10383):1159-71.ย
IMM-GB-2400303 | Date of Prep: April 2025
